Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
_Rupak_Singla_256_384.jpg)
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Subscribe To Our Newsletter & Stay Updated
